Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice

OBJECTIVES To assess the 3‐year efficacy and safety of the selective α1‐blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in ‘real‐life practice’. The influence of treatment response on the risk of acute urinary ret...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BJU international 2008-04, Vol.101 (7), p.847-852
Hauptverfasser:	Vallancien, Guy, Emberton, Mark, Alcaraz, Antonio, Matzkin, Haim, Van Moorselaar, R. Jeroen A., Hartung, Rudolf, Harving, Niels, Elhilali, Mostafa
Format:	Artikel
Sprache:	eng
Schlagworte:	acute urinary retention Adrenergic alpha-Antagonists - administration & dosage Aged alfuzosin Biological and medical sciences BPH Disease Progression Erectile Dysfunction - drug therapy Gynecology. Andrology. Obstetrics Humans LUTS Male Male genital diseases Medical sciences Nephrology. Urinary tract diseases Nocturia - drug therapy Patient Satisfaction Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - surgery Prostatism - drug therapy Quality of Life Quinazolines - administration & dosage Sexual Dysfunction, Physiological - drug therapy Treatment Outcome Tumors Tumors of the urinary system Urinary Retention - drug therapy Urinary tract. Prostate gland α1‐blockers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!